Heparin-Induced Thrombocytopenia - Retrospective Analysis of Data on Incidence and Outcomes Study
NCT01178333 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 668
Last updated 2015-05-22
Summary
HIT-RADIO is a study of patients who had a positive heparin PF-4 antibody test between 1/21/2008 and 9/25/2008 at selected hospitals. The study will collect and analyse information that is already in the patients' medical records. Information about laboratory values (such as platelet counts), treatments (such as medications), and outcomes (such as blood clots, amputation, and death) will be included.
Conditions
- Heparin Induced Thrombocytopenia
Sponsors & Collaborators
-
National Heart, Lung, and Blood Institute (NHLBI)
collaborator NIH -
Carelon Research
lead OTHER
Principal Investigators
-
Susan F Assmann, PhD · Carelon Research
-
David Kuter, MD · Massachusetts General Hospital
-
Eliot Williams, MD PHD · University of Wisconsin, Madison
-
Kenneth Friedman, MD · Versiti
-
Ronald Go, MD · Gunderson Clinic
-
Keith McCrae, MD · The Cleveland Clinic
-
Ellis Neufeld, MD PHD · Boston Children's Hospital
-
Lynne Uhl, MD · Beth Israel Deaconess Medical Center
-
Judith Lin, MD · Brigham and Women's Hospital
-
James Bussel, MD · Cornell University
-
Thomas Ortel, MD PHD · Duke University
-
Jodi Segal, MD MPH · Johns Hopkins University
-
Barbara Konkle, MD · Bloodworks
-
Cindy Leissinger, MD · Tulane University
-
Thomas Raife, MD · University of Iowa
-
Ann Zimrin, MD · University of Maryland Greenebaum Cancer Center
-
Jeffrey McCullough, MD · University of Minnesota
-
Nigel Key, MD · University of North Carolina, Chapel Hill
-
Bruce Sachais, MD PHD · University of Pennsylvania
-
Joseph Kiss, MD · University of Pittsburgh Institute for Transfusion Medicine
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-06-30
- Primary Completion
- 2010-12-31
- Completion
- 2010-12-31
Countries
- United States
Study Locations
More Related Trials
-
Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
NCT00673439 ·Status: TERMINATED ·Phase: PHASE2
-
The HIT-TRAP Trial
NCT00196417 ·Status: UNKNOWN ·Phase: PHASE4
-
EMR Tool Impact on HIT Documentation and Management
NCT05439265 ·Status: COMPLETED
-
Heparin-Induced Thrombocytopenia Score Card Study
NCT00489437 ·Status: COMPLETED ·Phase: PHASE1
-
An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
NCT05333861 ·Status: NOT_YET_RECRUITING
-
Validating 4Ts for Heparin Induced Thrombocytopenia (HIT)
NCT00946400 ·Status: UNKNOWN
-
This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)
NCT02859909 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)
NCT03594045 ·Status: TERMINATED ·Phase: PHASE2
-
Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
NCT00861692 ·Status: COMPLETED ·Phase: PHASE2
-
The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP
NCT03377439 ·Status: UNKNOWN
-
Bleeding In Thrombocytopenia Explained
NCT03505086 ·Status: RECRUITING
-
Value of Platelet Indices as Predictive Factor in Thrombocytopenia
NCT05116033 ·Status: UNKNOWN
-
Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura
NCT04323748 ·Status: RECRUITING ·Phase: PHASE1
-
The Study of Different Dose Rituximab in the Treatment of ITP
NCT03258866 ·Status: COMPLETED ·Phase: PHASE4
-
ITP Registry and Accompanying Biospecimen Collection
NCT05152238 ·Status: RECRUITING
-
Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia
NCT01317966 ·Status: WITHDRAWN
-
Optimizing the Diagnosis of Heparin Induced Thrombocytopenia
NCT03148912 ·Status: UNKNOWN ·Phase: NA
-
The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.
NCT01101295 ·Status: UNKNOWN
-
Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients
NCT05311930 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.
NCT01440361 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP
NCT06838949 ·Status: RECRUITING ·Phase: PHASE2
-
NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURpura of Adults
NCT01172015 ·Status: COMPLETED ·Phase: NA
-
A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia (ITP)
NCT02137681 ·Status: WITHDRAWN ·Phase: PHASE3
-
Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
NCT01933035 ·Status: COMPLETED
-
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
NCT06291415 ·Status: WITHDRAWN ·Phase: PHASE1